- Home
- DLXY vs CLRB Comparison
DLXY vs CLRB Comparison
Compare DLXY & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DLXY | CLRB |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 12.8M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | DLXY | CLRB |
|---|---|---|
| Price | $0.91 | $2.97 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 59.3K | ★ 120.3K |
| Earning Date | 03-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1077.13 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $273,155,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.61 | $2.45 |
| 52 Week High | $7.16 | $20.60 |
Technical Indicators
Market Signals| Indicator | DLXY | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 49.55 | 39.14 |
| Support Level | $0.82 | $3.15 |
| Resistance Level | $1.12 | $3.26 |
| Average True Range (ATR) | 0.13 | 0.24 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 32.81 | 5.61 |
Price Performance
Historical ComparisonAbout DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.